U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06393738) titled 'A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma' on April 25.
Brief Summary: This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.
ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Study Type: Interventional
...